Sage Journals: Discover world-class research

Abstract

Paeoniflorin (PF) is an important pharmacological component of some Chinese traditional herbal formulas, such as Bai Shao, Chi Shao, and Dan Pi, which have been clinically used for centuries. Although many experimental studies have explored a wide range of pharmacological properties of PF, including anticancer, anti-inflammatory, antioxidant, immunoregulatory, and prevention of insulin resistance, there is no review to describe these reported effects systematically, especially the antitumor effect and the underlying mechanisms. In this review, we summarize the recent progress on the anticancer profiles both in vitro and in vivo of PF. Moreover, we highlight the integrated molecular mechanisms of PF and contemplate its future prospects as a potential anticancer drug.

Keywords

paeoniflorin anticancer mechanisms apoptosis cell cycle

Ethnopharmacological products have always been a major aspect in the prevention and treatment of cancer and other diseases around the world, especially in Asia and Africa.^1
-3 Their multiple pharmacological properties have not only provided a theoretical basis for the mechanism study of natural compounds but also have shown great potential for drug discovery.^4,5 The exploration of anticancer agents from natural sources started with the discovery of vinblastine and vincristine in 1950,^6,7 and from then on, more and more ingredients with anticancer activity have been isolated from plants, such as taxanes, anthracyclines, and podophyllotoxin.⁸

Paeoniflorin (PF, Figure 1), an important pharmacologically active component derived from Bai Shao, Chi Shao, and other plants,^9

-13 is abundant in the fibrous root, bark-free root, and root bark of Paeonia lactiflora.¹⁴ Recently, PF has drawn great interest from researchers because of its variety of pharmacological activities including anti-inflammatory, antioxidant, immunoregulatory, prevention of insulin resistance, as well as liver and nerve protective effects.^15

-20 In addition, numerous studies are emerging which suggest that PF may have potent effects on a wide range of cancers.^21

-24 Although many experimental studies have explored plenty of pharmacological properties of PF, there is lack of review that systematically describes these reported effects, especially the antitumor effect and its underlying mechanisms. In this review, we summarize the recent progress on the anticancer profiles both in vitro (Table 1) and in vivo of PF. Moreover, we highlight the integrated molecular mechanisms (Table 1) of PF and contemplate its future prospects as a potential anticancer drug.

Figure 1

(a) Plant sources of paeoniflorin. (b) Synthesis of paeoniflorin.

Table 1

Anticancer Effects and Mechanisms of Paeoniflorin on Various Cancer Cell Lines.

Anticancer effects	Cell lines	IC₅₀ (µM)	Cytotoxicity assay	Molecular targets	Ref.
Cell cycle arrest	HOS, Saos-2	>100	MTS assay	Bcl-2 X-associated protein↑, Bcl-2↓	²⁵
	A549	11.4	XTT assay	p21/WAF1↑, Fas/APO-1↑	²⁴
	HCT116			FoxM1↓	²⁶
Apoptosis	HeLa	>100	MTT assay	Bcl‐2↓, Bax↑, Caspase-3↑	²⁷
	HOS, Saos-2	>100	MTS assay	Bcl-2 X-associated protein↑, Bcl-2↓	²⁵
	U937			MAPK↑, ERK↑, JNK↑	²⁸
	BXPC-3	82.19	MTT assay	MMP-9↓, ERK↓	²⁹
	RL95-2			MAPK↑, NF-κB↑	³⁰
	RT4			STAT3↓	³¹
	U87, U251	>100	CCK-8 assay	STAT3↓, Skp2↓, TLR4↓	³²
	MGC-803			microRNA-124↑, PI3K/Akt↓, STAT3↓	³³
	U87			microRNA-16↑, MMP-9↓	³⁴
	SKO-007			microRNA-29b↑, MMP-2↓	³⁵
	Capan-1, MIAPaCa-2	>100	PrestoBlue Cell viability reagent	HTRA3↑	²²
	HepG2, SMMC-7721			Prostaglandin E receptor EP2↓	³⁶
	HCT116			FoxM1↓	²⁶
	HL-60	>100	MTT assay	Fos-Jun↓	²¹
	A549			p21/WAF1↑, Fas/APO-1↑	²⁴
Inhibition of cell invasion, migration, and EMT	HepG2, Bel-7402			MMP-9↓, ERK↓, E-cadherin↑	³⁷
	U87, U251, T98G			MMP2/9↓, TGF-β↓	³⁸
	HCT116, SW480	>100	CCK-8 assay	HDAC2↓, E-cadherin↑, Vimentin↓	²³
	MDA-MB-231, MCF-7		Lactate dehydrogenase assay,Trypan blue exclusion assay	Notch-1↓, HIF-1α↓, PI3K/Akt↓	^36,39
	HCT116			FoxM1↓	²⁶
Overcome MDR	SGC7901/VCR	>100	MTT assay	NF-κB↓, MDR1↓, Bcl-XL↓, Bcl-2↓	⁴⁰

APO-1, apoptosis-1; EMT, epithelial-to-mesenchymal transition; ERK, extracellular signal-regulated kinase; CCK-8, Cell Counting Kit-8; MAPK, mitogen-activated protein kinase; MDR, multi-drug resistance; MMP, matrix metalloproteinase; MTT, (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt; WAF1, wild-type p53-activated fragment 1; XTT, (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide).

Sources of PF

Plant Sources

Paeonia lactiflora and Paeonia suffruticosa are the most frequently reported plants which contain PF.^9,13 Paeoniae Radix Alba (Baishao in Chinese) and Paeoniae Radix Rubra (Chishao in Chinese), the dried root of P. lactiflora Pall., are the main ingredients in some Chinese traditional herbal formulas which have been clinically used for the treatment of liver diseases⁴¹ and blood-stasis syndrome⁴² for centuries. Dan Pi (literally, Tree Peony Bark), another traditional Chinese medicine material, derived from the root cortex of P. suffruticosa, is clinically used for the treatment of various diseases, such as macula and menstrual disorders.⁴³ In addition, PF is also found in Cimicifuga foetida.⁴⁴ The plant sources of PF are summarized in Figure 1(a).

It is known that plenty of factors can affect the content of secondary metabolites in plants, including the location, age, and growth conditions. The content of PF in different parts of P. lactiflora Pall. ranges from 0.16% to 6.91%. The content in the dry stem (0.16%) is less than that of the root (6.89%).⁴⁵ When collected in May, the content of PF in roots was less than 3.05%, whereas in August it was 4.72%.⁴⁶Furthermore, the amount of PF increased with age, with yields of 3.26%, 3.30%, 3.36%, and 3.41% separately from 1- to 4-year-old plants.⁴⁷ In addition, proper levels of Mn, Fe, Zn, and Cu in the fertilizer facilitate the content of PF.⁴⁸ The content of PF in fleshy roots was not significantly different between wild and bud asexually cultivated plants.⁴⁹

Moutan cortex is derived from P. suffruticosa Andr., the content of PF of which ranged from 1.34% to 3.69%.⁵⁰ Other contents reported were 1.62%,⁵¹ 1.48%, and 0.71%.⁵²

Synthesis

PF can also be prepared synthetically (Figure 1(b)).^53
-55 To some extent, chemical synthesis is more targeted and more productive, but there are also many problems, such as many by-products and cumbersome procedures. Therefore, more efficient synthesis and/or isolation methods of PF should be further explored.

Anticancer Activity In Vitro and In Vivo

Abundant research has shown the anticancer effects of PF and provides evidence for it being a promising agent in cancer treatment. PF showed strong cytotoxic potential against human lung cancer A549 cells with an IC₅₀ value of 11.4 µM.²⁴ In addition, PF displayed cytotoxicity on multidrug resistant gastric cancer cell line SGC7901/VCR,⁴⁰ but on drug-resistant CEM/ADR5000 cells, the IC₅₀ value of PF was above 800 µM, suggesting that it had only slight toxicity on CEM/ADR5000 cells.⁵⁶ In addition, the inhibitory effect of PF on various human colorectal cancer cell lines, including HCT116, SW480, HT-29, and Caco-2 cells, is also slight, with IC₅₀ values ranging from 0.82 to 13.34 mM.^23,56,57 Recently, PF was proved to display a cell growth inhibitory effect on cervical cancer Hela,²⁷ glioma U87 and U251 cells,⁵⁸ and osteosarcoma HOS and Saos-2 cells.²⁵

PF has also demonstrated an anticancer effect in vivo. Wang used a U87-luciferace orthotopic xenograft mouse model to prove the in vivo effect of PF on glioblastoma and found that tumor volumes were markedly decreased and mouse survival rates were enhanced after intraperitoneal injection with PF (400 mg kg⁻¹ day⁻¹).³² Similarly, orally feeding with PF (1 g kg⁻¹ day⁻¹) also decreased glioblastoma growth in a U87 xenograft mouse model.³⁸ A RT4 cell xenograft nude mice model was established to determine if PF could inhibit bladder tumor growth in vivo, the results showed that intraperitoneal administration of PF (100 mg kg⁻¹ day⁻¹) reduced the weight and volumes of the tumor tissue.³¹ Additionally, by oral gavage feeding of PF at 1 g kg⁻¹ day⁻¹, PF reduced the tumor volume by 30.8% and had a stronger growth inhibitory effect and lower blood toxicity than that of docetaxel.⁵⁷ In summary, these studies indicated that PF has a variety of antitumor activities.

The Anticancer Mechanisms of PF

Cell Cycle Arrest

It is reported that PF displays an inhibitory effect on A549 cells by blocking cell cycle progression at G₀/G₁ phase, which may be correlated with p53-independent induction of p21/wild-type p53-activated fragment 1.²⁴ PF also blocks cell cycle progression at G₀/G₁ phase in colorectal cancer cells and downregulates FoxM1 to inhibit cell growth.²⁶ Besides, PF induces G₂/M phase cell cycle arrest in osteosarcoma HOS and Saos-2 cell lines. The expression levels of cell cycle regulators such as cyclin B1, p-CDK1, CDK1, and p21 significantly increased after PF treatment.²⁵ Interestingly, PF treatment for 12 hours significantly caused G₂/M phase arrest in HT29 cells, but later a strong G₁ phase arrest was detected at 24 and 48 hours. Further research demonstrated that cell cycle arrest may be mediated by p53 upregulation and 14-3-3ζ downregulation.⁵⁷

Apoptosis

Caspase and Bcl-2 protein family

Caspase and the Bcl-2 protein family are key regulators of apoptosis. Caspase activation is found in a great number of cancer cells after PF treatment. For instance, PF significantly increases caspase-3 activation in HepG2, SMMC-7721,⁵⁹ Hela,²⁷ and MGC-803 cells.³³ PF was also reported to upregulate both cleave caspase-3 and -9 in prolactinoma MMQ cells in a concentration-dependent manner.⁶⁰ Activation of caspase-3 and -9 was also detected in PF-treated BXPC-3,²⁹ SKO-007,³⁵ and HT29 cells.⁵⁷ Yang et al found that PF increased the activities of caspase-3, caspase-8, and caspase-9, thus inducing apoptosis in bladder carcinoma RT4 cells.³¹ It is believed that the upregulation of pro-apoptosis factor Bax and the downregulation of anti-apoptosis factor Bcl-2 lead to cell apoptosis. As shown in some research, PF increases the Bax-to-Bcl-2 ratio in HepG2, SMMC-7721,⁵⁹ HeLa,²⁷ RT4,³¹ MMQ,⁶⁰ HOS, and Saos-2 cells.²⁵

Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway

ERK, a subfamily of MAPK, is deeply involved in the occurrence and development of tumors. The MAPK/ERK pathway is reported to mediate cell proliferation, differentiation, and signal transduction.⁶¹ When exposed to stressors, the MAPK/ERK pathway contributes to apoptosis by affecting the activity of the apoptosis-related Bcl-2 family of proteins.⁶² Yang indicated that the inhibition of ERK by PF significantly contributes to pancreatic cancer cell apoptosis.²⁹ This result is supported by other research demonstrating that PF facilitates HL-60 cell apoptosis by blocking the Fos-Jun heterodimer-binding site of AP-1, which is a downstream target gene of the MAPK family.²¹ However, PF exerts a growth inhibitory effect by activating the MAPK pathway in endometrial cancer cells.³⁰ How to explain the contradictory outcome and what role MAPK/ERK actually plays in cancer needs further investigation.

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway

NF-κB is of great significance in tumorigenesis and tumor progression. The constitutive activation of NF-κB, which was proved to mediate the expression of apoptosis-related genes such as Bcl-2, has been found in many types of cancers.⁶³ Wu tested whether PF displays cytotoxicity through NF-κB pathway inhibition and found PF suppresses NF-κB activation in a dose- and time-dependent manner. Further investigation proved that the inhibition of phosphorylation and degradation of IκBα by PF contributes to NF-κB inhibition. Other research indicated that the inhibition of NF-κB by PF enhances 5-fluorouracil-induced gastric carcinoma cell apoptosis.⁶⁴ However, Zhang et al found that PF inhibits endometrial cancer cell growth by activating the NF-κB signaling pathway, indicating that NF-κB plays a dual role in PF-induced cell death and its effect depends on cell type and cell circumstance.³⁰

STAT3 pathway

STAT3, an important oncogene modulating cancer cell proliferation, invasion, metastasis, apoptosis, and immune escape, was proved to regulate the expression of different types of apoptosis-related genes such as Bcl-2 and Bax.^65,66 Targeting STAT3 to inhibit its phosphorylation may be a strategy to combat tumor occurrence and development.⁶⁷ A recent study by Zheng demonstrated that PF significantly inhibits the expression of PI3K, Akt, p-Akt, and p-STAT3 in MGC-803 cells. This effect may result from the upregulation of microRNA-124. The role of STAT3 is confirmed by the experimental result that the overexpression of STAT3 abrogates the inhibitory effect of PF on MGC-803 cells.³³ Similarly, research by Nie also revealed the inhibitory effect of PF on STAT3 and its downstream molecules in glioma cells U87 and U251. Besides, they further illuminated that the degradation of STAT3 is mainly through the ubiquitin-proteasome pathway.⁶⁸ In addition, PF also exerts its growth inhibitory effect on bladder carcinoma RT4 cells via suppressing STAT3 phosphorylation in vivo and in vitro.³¹

Matrix metalloproteinases (MMPs)

MMP-2 and -9 play vital roles, not only in tumor invasion and metastasis, which is related to the degree of cancer malignancy, but also in cancer cell death. It is reported that the downregulation of MMP-9 and ERK signaling participates in PF-induced pancreatic cancer cell apoptosis.²⁹ Li demonstrated that PF accelerates glioma cell apoptosis via MMP-9 downregulation, which may be attributed to the upregulation of microRNA-16.³⁴ Similar to this study, PF promoted the apoptosis of multiple myeloma through MMP-2 downregulation, which is regulated by an increased level of microRNA-29b.³⁵

Other signaling pathways

Hu demonstrated that the downregulation of PGE2 receptor subtype EP2 induced by PF contributes to HepG2 and SMMC-7721 cell apoptosis.⁵⁹ Wang found that PF effectively suppresses TLR4 and its downstream molecules both in vivo and in vitro, and the overexpression of TLR4 abolishes the antiproliferation effect of PF, indicating that targeting TLR4 may be a novel mechanism for PF-induced cell death. This study also focused on the way of TLR4 degradation and revealed that PF promotes Triad3A to conjugate with TLR4, which leads to Triad3A-dependent ubiquitin degradation of TLR4.³² Besides, PF-induced Notch-1 suppression plays a part in breast cancer cell apoptosis, which was indicated by an article describing that the overexpression of Notch-1 reverses PF-induced cell death and the knockdown of Notch-1 enhances the inhibitory effect of PF.³⁶ Global analysis of gene expression showed that HTRA3 is the most increased gene upon PF treatment in Capan-1 cells; further investigation demonstrated that HTRA3 increases the expression level of Bax, thus inducing pancreatic cancer cell apoptosis.²² A novel study revealed that by inhibiting prolactin, PF induces prolactinoma cell apoptosis through the mitochondria-dependent pathway, which is related to phosphorylated P53 upregulation.⁶⁰ Moreover, PF-induced apoptosis of A549 cells is due to activation of the Fas/Fas ligand apoptotic system, reflected in the increased expression of Fas/apoptosis-1 and its 2 ligands.²⁴

PF is reported to have a cytotoxic effect on HL-60 and other leukemia cell lines through the inhibition of Fos-Jun-DNA complex formation.²¹ However, in human leukemia U937 cells, Lim found that PF had no inhibitory effect although gene expression profiling demonstrated that PF changes the expression of apoptosis-related genes. Using a comparative global transcription analysis, PF was observed to activate the c-Jun N-terminal kinase (JNK) pathway less when compared with anisomycin treatment, but activate the fibroblast growth factor (FGF) signaling and MAPK pathway, which may be the explanation of this phenomenon.²⁸

Inhibition of Migration and Invasion

Epithelial-to-mesenchymal transition (EMT), a process of losing cell-to-cell adhesion, has been reported to play an essential role in tumor invasion and metastasis, which have always been a tough problem in cancer cure. Activation of EMT promotes cancer cell migration and invasion, so seeking compounds that can inhibit EMT is an urgent task nowadays. PF is proved to suppress migration and invasion in glioblastoma through the inhibition of transforming growth factor-β(TGF-β)-induced EMT, while the expression level of EMT markers such as snail, vimentin, N-cadherin, and MMP-2 and -9 reduces after PF treatment. These results were also confirmed in vivo using a U87 xenograft mouse model.³⁸ Lu demonstrated that PF significantly inhibits invasion, metastasis, and adhesion of HepG2 and Bel-7402 cells; this effect is mediated by the downregulation of MMP-9 and ERK and the upregulation of E-cadherin.³⁷ Besides, PF inhibits invasion in breast cancer MCF-7 and MDA-MB-231 cells through suppressing the Notch-1 signaling pathway.³⁶ Another study focused on hypoxia-induced EMT in breast cancer cells and found that PF restrains hypoxia-induced EMT in MDA-MB-231 cells by inhibiting HIF-1α expression, which is modulated by the PI3K/Akt signaling pathway.³⁹ HDAC2 is proved to participate in EMT of colorectal cancer cells. PF potently inhibits cell migration and invasion through the suppression of HDAC2-induced EMT, the downregulation of vimentin, and the upregulation of E-cadherin. Besides, the anticolorectal cancer effect is also verified in the tumor xenograft model.²³ Other research demonstrated that PF could reduce metastasis of Lewis lung cancer cell xenografts partly through inhibiting the alternative activation of macrophages.⁶⁹

Combat Multi-Drug Resistance (MDR)

During chronic treatment, various types of cancer cells gain acquired resistance to chemotherapeutic drugs, leading to treatment failure and high mortality in cancer therapy, so finding agents that can sensitize multi-drug resistance (MDR) cancer cells to chemotherapeutic drugs may be a strategy to combat multi-drug resistance. PF is reported to modulate MDR and sensitize SGC7901/VCR cells to VCR-induced apoptosis via the inactivation of NF-κB and its target genes MDR1, BCL-XL, and BCL-2.⁴⁰ In addition, PF increases the cytotoxicity of doxorubicin in CEM/ADR5000 and Caco-2 cells with a reversal ratio 2.32 and 1.50, respectively. This reversal effect is partly through inhibiting ABC transporters in CEM/ADR5000, but in Caco-2 cells, PF does not inhibit ATP-binding cassette (ABC) transporters, and the downregulation of AhR, CYP1A1, and GSTP1 may contribute to the reversal effect.⁵⁶

Discussion

In summary, PF is the main active ingredient of many Chinese herbal medicines, such as Bai Shao, Chi Shao, and Dan Pi. It has been demonstrated that PF has a wide spectrum of biological activities. Specially, it has significant and potent anticancer effects on various types of cancer, including leukemia, glioma, pancreatic, breast, and colorectal. Overall, the anticancer effect of PF is related to cell apoptosis, cell cycle arrest, EMT inhibition, and MDR reversal. It is reported that MMP-2, MMP-9, MAPK/ERK, JNK, STAT3, PI3K/Akt, NF-κB, Notch-1, and other signaling pathways may be involved in PF-induced cell death, but the target of PF remains unknown. Moreover, in different cancer cells, the antitumor mechanisms of PF are also different. How PF affects cancer cells may depend on a specific receptor located in the cell membrane, but the downstream regulators are almost the same, such as the caspase family in apoptosis, and MMP-2, MMP-9, and E-cadherin in EMT. Although PF displays a potent anticancer effect, the molecular target and signaling pathway have not been fully elucidated. Further research needs to be carried out in order to clarify this question.

Some research also revealed the growth inhibitory effect of Paeoniae Radix extract (PRE), which includes PF, gallic acid, benzoic acid, paeonol, and other active components.⁷⁰ Lee reported that PRE induces hepatoma cell apoptosis in a p53-independent pathway.⁷¹ The antibladder cancer effect of Radix Paeoniae Rubra extract was proved in vitro and in vivo.⁷² In addition, WU reported that the extract of Paeoniae Radix and Astragalus membranaceus (PAE) displayed an inhibitory effect on proliferation, migration, and invasion of hepatoma cells HepG2 and SMMC-7721, providing evidence for PAE as a promising agent for HCC treatment.⁷³ It is generally recognized that traditional Chinese medicines have multiple targets distinguished from monomeric compounds, so whether PF displays a stronger anticancer effect than the complex mixture PRE and their different mechanisms needs further determination.

Combination drug therapy is widely applied in clinical practice. As mentioned above, PF enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells.⁶⁴ In addition, the anticancer effect of Erlotinib can also be reinforced by PF, which directly suppresses ErbB3 phosphorylation, indicating that Erlotinib in combination with PF is more effective than its use alone.⁷⁴ We believe more and more combination drug strategies between PF and other agents will be created in the future.

Although the therapeutic potential of PF looks promising in vitro and in vivo preclinical studies, several hurdles still exist in the current stage. Toxicity is an important issue with PF. It is worth synthesizing derivatives of PF with more selectivity and efficacy, and reducing the unexpected side effects. Additionally, there is little literature related to the pharmacokinetic profiles of PF, including absorption, distribution, metabolism, and excretion. Therefore, further pharmacokinetic and clinical studies are mandated to define the efficacy and safety of PF in cancer and other diseases.

Footnotes

Acknowledgments

The pictures of plants and Chinese medicines used in this article were obtained online: https://image.baidu.com. The databases used in this article were TCMSP: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform http://lsp.nwu.edu.cn/tcmsp.php and SymMap: http://www.symmap.org/;

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research,authorship,and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research,authorship,and/or publication of this article: This work was supported by the National Science Foundation of China (81803790).

References

Tariq

Sadia

Pan

et al. A systematic review on ethnomedicines of anti-cancer plants. Phytother Res. 2017;31(2):202-264.doi:10.1002/ptr.5751

Yan

Lai

Lin

. Anticancer properties of traditional Chinese medicine. Comb Chem High Throughput Screen. 2017;20(5):423-429.doi:10.2174/1386207320666170116141818

Baskar

AA.

Numair

KSA.

Alsaif

MA.

Ignacimuthu

. In vitro antioxidant and antiproliferative potential of medicinal plants used in traditional Indian medicine to treat cancer. Redox Rep. 2012;17(4):145-156.doi:10.1179/1351000212Y.0000000017

Yan

XJ.

Gong

LH.

Zheng

FY.

Cheng

KJ.

Chen

ZS.

Shi

. Triterpenoids as reversal agents for anticancer drug resistance treatment. Drug Discov Today. 2014;19(4):482-488.doi:10.1016/j.drudis.2013.07.018

Xue

YQ.

JM.

Luo

Cheng

K-J.

Wei

Shi

. Resveratrol oligomers for the prevention and treatment of cancers. Oxid Med Cell Longev. 2014;2014(5):765832-9.doi:10.1155/2014/765832

Cragg

GM.

Newman

. Plants as a source of anti-cancer and anti-HIV agents. Ann Appl Biol. 2003;143(2):127-133.doi:10.1111/j.1744-7348.2003.tb00278.x

Cragg

GM.

Newman

. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1-2):72-79.doi:10.1016/j.jep.2005.05.011

Mukherjee

AK.

Basu

Sarkar

Ghosh

. Advances in cancer therapy with plant based natural products. Curr Med Chem. 2001;8(12):1467-1486.doi:10.2174/0929867013372094

Kim

SH.

Lee

MK.

Lee

KY.

Sung

SH.

Kim

. Chemical constituents isolated from Paeonia lactiflora roots and their neuroprotective activity against oxidative stress in vitro. J Enzyme Inhib Med Chem. 2009;24(5):1138-1140.doi:10.1080/14756360802667977

10.

et al. Chemical constituents from water-soluble extract of dry roots of Paeonia lactiflora]. Zhongguo Zhong Yao Za Zhi. 2018;43(14):2956-2963.

11.

Wang

et al. Discrimination and chemical characterization of different Paeonia lactifloras (Radix Paeoniae Alba and Radix Paeoniae Rubra) by infrared macro-fingerprint analysis-through-separation. J Mol Struct. 2015;1099:68-76.doi:10.1016/j.molstruc.2015.06.035

12.

Yang

Chow

YI.

Zhu

. The comparative study on bioactivities of Radix Paeoniae Alba and Radix Paeoniae Rubra. Planta Med. 2013;79(10):833-833.doi:10.1055/s-0033-1348583

13.

Lau

CH.

Chan

CM.

Chan

et al. Pharmacological investigations of the anti-diabetic effect of Cortex Moutan and its active component paeonol. Phytomedicine. 2007;14(11):778-784.doi:10.1016/j.phymed.2007.01.007

14.

Yuan

Jiang

et al. Functional diversity of genes for the biosynthesis of paeoniflorin and its derivatives in Paeonia. Int J Mol Sci. 2013;14(9):18502-18519.doi:10.3390/ijms140918502

15.

Zhang

Dou

Zhang

et al. Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 2014;306(1):G27-G36.doi:10.1152/ajpgi.00465.2012

16.

Lin

Wang

et al. Paeoniflorin attenuated oxidative stress in rat COPD model induced by cigarette smoke. Evid Based Complement Alternat Med. 2016;2016(9):1698379-9.doi:10.1155/2016/1698379

17.

D-Y.

Dai

S-M

. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall., a traditional chinese herbal medicine. Front Pharmacol. 2011;2:10.doi:10.3389/fphar.2011.00010

18.

Liu

Wang

Guan

Chu

. Paeoniflorin suppresses lipid accumulation and alleviates insulin resistance by regulating the Rho kinase/IRS-1 pathway in palmitate-induced HepG2Cells. Biomed Pharmacother. 2017;90:361-367.doi:10.1016/j.biopha.2017.03.087

19.

Chu

Liu

et al. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Sci Rep. 2017;7(1):44819.doi:10.1038/srep44819

20.

Zhang

Wang

LL.

et al. Paeoniflorin attenuates hippocampal damage in a rat model of vascular dementia. Exp Ther Med. 2016;12(6):3729-3734.doi:10.3892/etm.2016.3849

21.

Kwon

Kim

KS.

Park

Lee

DK.

Yang

. Inhibitory effect of Paeoniflorin on Fos-Jun-DNA complex formation and stimulation of apoptosis in HL-60 cells. J Biochem Mol Biol. 2001;34(1):28-32.

22.

Gong

et al. Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. Drug Des Devel Ther. 2017;11:2481-2491.doi:10.2147/DDDT.S134518

23.

Zhang

JW.

L-X.

W-Z.

Pan

T-J.

Yang

Z-S.

Yang

Y-K

. Anti-Tumor effects of paeoniflorin on epithelial-to-mesenchymal transition in human colorectal cancer cells. Med Sci Monit. 2018;24:6405-6413.doi:10.12659/MSM.912227

24.

Hung

JY.

Yang

CJ.

Tsai

YM.

Huang

HW.

Huang

. Antiproliferative activity of paeoniflorin is through cell cycle arrest and the Fas/Fas ligand-mediated apoptotic pathway in human non-small cell lung cancer A549 cells. Clin Exp Pharmacol P. 2008;35(2):141-147.

25.

Jin

LB.

Zhu

Liang

et al. Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells. Mol Med Rep. 2018;17(4):5095-5101.

26.

Yue

Yan

GQ.

Kang

ZH.

. Paeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells. Cell Cycle. 2018;17(2):240-249.doi:10.1080/15384101.2017.1407892

27.

Zhang

. Modulating Bcl-2 family proteins and caspase-3 in induction of apoptosis by paeoniflorin in human cervical cancer cells. Phytother. Res.. 2011;25(10):1551-1557.doi:10.1002/ptr.3534

28.

Lim

SH.

Ahn

KS.

Kim

SH.

Jang

. Gene expression profiling reveals that paeoniflorin has an apoptotic potential in human leukemia U937 cells. Mol Cell Toxicol. 2009;5(4):335-345.

29.

Yang

Cui

Han

et al. Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP-9 and ERK signaling. Oncol Lett. 2016;12(2):1471-1476.doi:10.3892/ol.2016.4761

30.

Zhang

JX.

Wang

FC.

Wang

et al. Paeoniflorin inhibits proliferation of endometrial cancer cells via activating MAPK and NF-kappa B signaling pathways. Experimental and Therapeutic Medicine. 2017;14(6):5445-5451.

31.

Yang

Ren

Lou

ZG.

Wan

Weng

GB.

Cen

. Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3. Acta Pharm. 2018;68(2):211-222.doi:10.2478/acph-2018-0013

32.

Wang

Liu

et al. Paeoniflorin inhibits glioblastoma growth in vivo and in vitro: a role for the Triad3A-dependent ubiquitin proteasome pathway in TLR4 degradation. Cancer Manag Res. 2018;10:887-897.doi:10.2147/CMAR.S160292

33.

Zheng

YB.

Xiao

GC.

Tong

et al. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol. 2015;21(23):7197-7207.doi:10.3748/wjg.v21.i23.7197

34.

Wei

et al. Paeoniflorin inhibits proliferation and induces apoptosis of human glioma cells via microRNA-16 upregulation and matrix metalloproteinase-9 downregulation. Mol Med Rep. 2015;12(2):2735-2740.doi:10.3892/mmr.2015.3718

35.

Wang

Liu

. Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA-29b and matrix metalloproteinase-2. Mol Med Rep. 2016;14(3):2143-2149.doi:10.3892/mmr.2016.5498

36.

Zhang

Yuan

Cui

Xiao

Jiang

. Paeoniflorin inhibits proliferation and invasion of breast cancer cells through suppressing Notch-1 signaling pathway. Biomed Pharmacother. 2016;78:197-203.doi:10.1016/j.biopha.2016.01.019

37.

Song

SS.

Wei

. Paeoniflorin inhibited the tumor invasion and metastasis in human hepatocellular carcinoma cells. Bratisl Lek Listy. 2014;115(7):427-433.

38.

Wang

Liu

et al. Paeoniflorin inhibits migration and invasion of human glioblastoma cells via suppression transforming growth factor β-induced epithelial-mesenchymal transition. Neurochem Res. 2018;43(3):760-774.doi:10.1007/s11064-018-2478-y

39.

Zhou

Wang

Song

. Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells. Onco Targets Ther. 2016;9:2511-2518.doi:10.2147/OTT.S102422

40.

Fang

Zhu

Zhang

Shu

Liu

. Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-kappaB activation. Mol Med Rep. 2012;5(2):351-356.

41.

Tao

YE.

Wen

Song

Wang

. Paeoniflorin attenuates hepatic ischemia/reperfusion injury via anti-oxidative, anti-inflammatory and anti-apoptotic pathways. Exp Ther Med. 2016;11(1):263-268.doi:10.3892/etm.2015.2902

42.

Mao

Yang

Hou

. Thrombosis recanalization by paeoniflorin through the upregulation of urokinasetype plasminogen activator via the MAPK signaling pathway. Mol Med Rep. 2016;13(6):4593-4598.doi:10.3892/mmr.2016.5146

43.

Lin

HC.

Ding

HY.

. Two novel compounds from Paeonia suffruticosa . J Nat Prod. 1998;61(3):343-346.doi:10.1021/np9704258

44.

Huyen

Luyen

Khan

et al. Chemical constituents from Cimicifuga dahurica and their anti-proliferative effects on MCF-7 breast cancer cells. Molecules. 2018;23(5):1083.doi:10.3390/molecules23051083

45.

Jian

ZY.

J-B.

Wang

W-Q

. RP-HPLC determination of main chemical components in different parts and different harvest periods of Paeonia lactiflora . Yao Xue Xue Bao. 2010;45(4):489-493.

46.

Feng

XF.

S-L.

Zhang

Y-X

et al. Dynamic change of paeoniflorin content in root of Paeonia lactiflora growing at Duolun County, Inner Mongolia. Zhongguo Zhong Yao Za Zhi. 2008;33(3):244-247.

47.

Yuan

XF.

Peng

SM.

Wang

BL.

Ding

. Effects of growth years of Paeonia lactiflora on bacterial community in rhizosphere soil and paeoniflorin content. Zhongguo Zhong Yao Za Zhi. 2014;39(15):2886-2892.

48.

Chen

Zhang

Wang

. Effects of Mn, Fe, Zn and Cu on growth and paeoniflorin content of Paeonia lactiflora . Zhongguo Zhong Yao Za Zhi. 2009;34(8):961-964.

49.

Xie

Zhou

et al. Comparative study of biological characters and paeoniflorin content of wild and asexual cultivated Paeonia lactiflora growing at Duolun County, Inner Mongolia. Zhongguo Zhong Yao Za Zhi. 2015;40(24):4830-4833.

50.

Guo

BL.

Basang

Xiao

PG.

Hong

. Research on the quality of original plants and material medicine of Cortex Paeoniae. Zhongguo Zhong Yao Za Zhi. 2002;27(9):654-657.

51.

Wang

ZQ.

Chen

Liu

et al. Morphological, microscopic, multiple-component assay and fingerprinting based systematic research on quality evaluation of Moutan Cortex (Paeonia suffruticosa). Zhongguo Zhong Yao Za Zhi. 2018;43(14):2899-2907.

52.

Chen

Zhang

Zhu

. Determination of glycosides and sugars in Moutan Cortex by capillary electrophoresis with electrochemical detection. J Pharm Biomed Anal. 2006;41(1):129-134.doi:10.1016/j.jpba.2005.11.001

53.

Corey

EJ.

. Total synthesis of (+/-)-paeoniflorigenin and paeoniflorin. J Am Chem Soc. 1993;115(19):8871-8872.doi:10.1021/ja00072a063

54.

Baltina

LA.

Kondratenko

RM.

Spirikhin

LV.

Baltina

. Synthesis of esters of the monoterpene glycoside paeoniflorin. Chem Nat Compd. 2016;52(2):347-349.doi:10.1007/s10600-016-1641-4

55.

Hatakeyama

Kawamura

Takano

. Total Synthesis of (-)-Paeoniflorin. J Am Chem Soc. 1994;116(9):4081-4082.doi:10.1021/ja00088a055

56.

Zhou

JX.

Wink

. Reversal of multidrug resistance in human colon cancer and human leukemia cells by three plant extracts and their major secondary metabolites. Medicines. 2018;5(4):123.doi:10.3390/medicines5040123

57.

Wang

Zhou

Wang

et al. Paeoniflorin inhibits growth of human colorectal carcinoma HT 29 cells in vitro and in vivo. Food Chem Toxicol. 2012;50(5):1560-1567.doi:10.1016/j.fct.2012.01.035

58.

Ouyang

et al. Paeoniflorin exerts antitumor effects by inactivating S phase kinase-associated protein 2 in glioma cells. Oncol Rep. 2018;39(3):1052-1062.doi:10.3892/or.2017.6175

59.

Sun

Wei

et al. Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis. Anticancer Drugs. 2013;24(2):140-149.doi:10.1097/CAD.0b013e32835a4dac

60.

Wei

Zhou

Ren

Wang

. The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway. J Cell Biochem. 2018;119(7):5704-5714.doi:10.1002/jcb.26752

61.

Amsterdam

Shezen

Raanan

et al. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer. Int J Oncol. 2011;39(3):649-656.doi:10.3892/ijo.2011.1090

62.

Guo

Yang

Jing

et al. Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling. Int J Nanomed. 2016;11:5257-5276.doi:10.2147/IJN.S112030

63.

Pikarsky

Porat

RM.

Stein

et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461-466.doi:10.1038/nature02924

64.

Wang

Shu

Liu

. Paeoniflorin suppress NF-κB activation through modulation of IκBα and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells. Biomed Pharmacother. 2008;62(9):659-666.doi:10.1016/j.biopha.2008.08.002

65.

JH.

Kim

. Role of Janus kinase/signal transducers and activators of transcription in the pathogenesis of pancreatitis and pancreatic cancer. Gut Liver. 2012;6(4):417-422.doi:10.5009/gnl.2012.6.4.417

66.

Scholz

Heinze

Detjen

et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003;125(3):891-905.doi:10.1016/S0016-5085(03)01064-3

67.

Wang

YX.

Cai

Jiang

Zhou

TB.

. Silibinin inhibits proliferation, induces apoptosis and causes cell cycle arrest in human gastric cancer MGC803 cells via STAT3 pathway inhibition. Asian Pac J Cancer Prev. 2014;15(16):6791-6798.doi:10.7314/APJCP.2014.15.16.6791

68.

Nie

XH.

Ou-yang

Xing

et al. Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway. Drug Des Devel Ther. 2015;9:5611-5622.doi:10.2147/DDDT.S93912

69.

Chen

GL.

Y-J.

Chen

Lin

. Paeoniflorin inhibits macrophage-mediated lung cancer metastasis. Chin J Nat Med. 2015;13(12):925-932.doi:10.1016/S1875-5364(15)30098-4

70.

Koo

YK.

Kim

JM.

Koo

et al. Platelet anti-aggregatory and blood anti-coagulant effects of compounds isolated from Paeonia lactiflora and Paeonia suffruticosa . Pharmazie. 2010;65(8):624-628.

71.

Lee

SM.

MLY.

Tse

et al. Paeoniae Radix, a Chinese herbal extract, inhibit hepatoma cells growth by inducing apoptosis in a p53 independent pathway. Life Sci. 2002;71(19):2267-2277.doi:10.1016/S0024-3205(02)01962-8

72.

Lin

M-Y.

Chiang

SY.

Y-Z

et al. Anti-tumor effect of Radix Paeoniae Rubra extract on mice bladder tumors using intravesical therapy. Oncol Lett. 2016;12(2):904-910.doi:10.3892/ol.2016.4698

73.

J-J.

Sun

W-Y.

S-S.

Zhang

Wei

. A standardized extract from Paeonia lactiflora and Astragalus membranaceus induces apoptosis and inhibits the proliferation, migration and invasion of human hepatoma cell lines. Int J Oncol. 2013;43(5):1643-1651.doi:10.3892/ijo.2013.2085

74.

Hao

Yang

Ding

et al. Paeoniflorin potentiates the inhibitory effects of erlotinib in pancreatic cancer cell lines by reducing ErbB3 phosphorylation. Sci Rep. 2016;6(1):32809.doi:10.1038/srep32809

The Anticancer Effects of Paeoniflorin and Its Underlying Mechanisms

Abstract

Keywords

Sources of PF

Plant Sources

Synthesis

Anticancer Activity In Vitro and In Vivo

The Anticancer Mechanisms of PF

Cell Cycle Arrest

Apoptosis

Caspase and Bcl-2 protein family

Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway

STAT3 pathway

Matrix metalloproteinases (MMPs)

Other signaling pathways

Inhibition of Migration and Invasion

Combat Multi-Drug Resistance (MDR)

Discussion

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

References